Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency
Andreu Crespo, M.A. ; Castro-Feijóo, L. ; Labarta-Aizpún, J.I. (Universidad de Zaragoza) ; Peral, C. ; Barrueta, J.A. ; Rubio-Rodríguez, D. ; Rubio-Terres, C.
Resumen: Objective: To analyze the cost-effectiveness of weekly somatrogon compared to daily growth hormones (GH-d) in the pediatric population of Spain with growth hormone deficiency (GHD).
Methods: Markov model with two states (patients with or without GH-d or somatrogon treatment) in prepubertal children (3 to 11 years and 3 to 12 years in girls and boys, respectively) with GHD in isolation or as part of multiple pituitary hormone deficiency and without previous treatment, from the perspective of the National Health System. The simulation of the economic model ends at the age of 18. The costs of hormones and monitoring were obtained from Spanish sources. The utilities were obtained from the literature. Spanish clinical experts validated the assumptions of the model.
Results: In the deterministic analysis, somatrogon would be cost-effective, compared to GH-d, with a cost per QALY (quality-adjusted life year) gained of €19,259 and a clinically relevant QALY gain (0.336). This result was confirmed in deterministic sensitivity analyses. According to the probabilistic analysis, somatrogon would be the dominant treatment, with a 61% probability of a willingness to pay of €25,000 per QALY gained.
Conclusion: Compared to GH-d, somatrogon is cost-effective in the Spanish pediatric population with GHD.
Idioma: Inglés
DOI: 10.1080/14737167.2023.2256473
Año: 2023
Publicado en: Expert Review of Pharmacoeconomics and Outcomes Research 23, 10 (2023), 1139-1146
ISSN: 1473-7167
Factor impacto JCR: 1.8 (2023)
Categ. JCR: HEALTH CARE SCIENCES & SERVICES rank: 101 / 174 = 0.58 (2023) - Q3 - T2
Categ. JCR: HEALTH POLICY & SERVICES rank: 72 / 118 = 0.61 (2023) - Q3 - T2
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 240 / 354 = 0.678 (2023) - Q3 - T3
Factor impacto CITESCORE: 4.0 - Pharmacology (medical) (Q2) - Health Policy (Q2)
Factor impacto SCIMAGO: 0.671 - Health Policy (Q2) - Pharmacology (medical) (Q2) - Medicine (miscellaneous) (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Pediatría (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2026-03-18-13:52:48)
Visitas y descargas
Methods: Markov model with two states (patients with or without GH-d or somatrogon treatment) in prepubertal children (3 to 11 years and 3 to 12 years in girls and boys, respectively) with GHD in isolation or as part of multiple pituitary hormone deficiency and without previous treatment, from the perspective of the National Health System. The simulation of the economic model ends at the age of 18. The costs of hormones and monitoring were obtained from Spanish sources. The utilities were obtained from the literature. Spanish clinical experts validated the assumptions of the model.
Results: In the deterministic analysis, somatrogon would be cost-effective, compared to GH-d, with a cost per QALY (quality-adjusted life year) gained of €19,259 and a clinically relevant QALY gain (0.336). This result was confirmed in deterministic sensitivity analyses. According to the probabilistic analysis, somatrogon would be the dominant treatment, with a 61% probability of a willingness to pay of €25,000 per QALY gained.
Conclusion: Compared to GH-d, somatrogon is cost-effective in the Spanish pediatric population with GHD.
Idioma: Inglés
DOI: 10.1080/14737167.2023.2256473
Año: 2023
Publicado en: Expert Review of Pharmacoeconomics and Outcomes Research 23, 10 (2023), 1139-1146
ISSN: 1473-7167
Factor impacto JCR: 1.8 (2023)
Categ. JCR: HEALTH CARE SCIENCES & SERVICES rank: 101 / 174 = 0.58 (2023) - Q3 - T2
Categ. JCR: HEALTH POLICY & SERVICES rank: 72 / 118 = 0.61 (2023) - Q3 - T2
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 240 / 354 = 0.678 (2023) - Q3 - T3
Factor impacto CITESCORE: 4.0 - Pharmacology (medical) (Q2) - Health Policy (Q2)
Factor impacto SCIMAGO: 0.671 - Health Policy (Q2) - Pharmacology (medical) (Q2) - Medicine (miscellaneous) (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Pediatría (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2026-03-18-13:52:48)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Pediatría
Registro creado el 2026-03-18, última modificación el 2026-03-18